Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Abuse rate of gabapentin, pregabalin far below that of opioids

Key clinical point: Abuse of gabapentin and pregabalin occurs but remains eclipsed by opioid abuse.

Major finding: The abuse exposure rate reported by poison control centers was 0.06, 0.01 and 0.4 per 100,000, respectively, for gabapentin, pregabalin, and opioids.

Study details: The findings are based on population analyses of three surveys tracking use of prescription drugs gabapentin, pregabalin and opioids.

Disclosures: Pfizer funded the research. The RADARS system is owned by Denver Health and Hospital Authority under the Colorado state government. RADARS receives some funding from pharmaceutical industry subscriptions. Dr. Asomaning and Diane L. Martire, MD, MPH, are Pfizer employees who have financial interests with Pfizer.

Commentary:

REPORTING FROM CPDD 2019